Skip to content

ASCO 2021 round-up

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting ASCO rapid guideline update for HER2-negative breast cancer Anew American Society of Clinical Oncology (ASCO) guideline update recommends offering one year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative…

Read More

Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced NPC

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to the findings of a phase 3 international study, presented at…

Read More

Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced oesophageal squamous cell carcinoma, particularly those positive for the…

Read More

Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase 3 international study, presented at the 2021 ASCO Annual Meeting, found that…

Read More

Immunotherapy delays disease recurrence in patients with early-stage lung cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Treatment with the immunotherapy checkpoint inhibitor atezolizumab extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research presented at…

Read More

Additional chemotherapy does not offer survival benefit for patients with locally advanced cervical cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side-effects, according to results of a phase 3 international trial presented at the…

Read More

Targeted radiotherapy offers new treatment option for castration-resistant prostate cancer

The investigational therapy 177Lu-PSMA-617 significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with standard of care alone, according to new research presented at the 2021 ASCO Annual Meeting. “This novel targeted radiotherapy could fill a significant need…

Read More

Lung cancer screening: Is Ireland ready?

In Ireland, lung cancer remains the most common cause of cancer-related deaths and accounts for more deaths per year than breast and prostate cancers combined Lung cancer remains the most common cause of cancer-related death in Ireland. During the period 2015-2017, there was an average of 1,884 deaths per year with 20 per cent of…

Read More

ISMO Travel Bursary Awards 2021

The ISMO meeting featured some of the best cancer research currently being undertaken in Ireland This year’s Irish Society of Medical Oncology (ISMO) annual meeting took place on Friday, 29 January 2021. As a result of Covid-19, the meeting was held virtually, streaming live from the Fintan Gunne Theatre, Catherine McAuley Centre, Mater Misericordiae University…

Read More

CPD Module- Cervical cancer

2 CPD Hours Authors Caitriona Duggan, Registered Advanced Nurse Practitioner, Oncology Department, Portiuncula Hospital, Ballinasloe, Co. Galway. This module outlines what ‘cervical’ is. It highlights the epidemiology, pathogenesis and risk factors of cervical cancer. The module summarises the staging and complex management options of the various stages that comprise cervical cancer. It also discusses cervical…

Read More
Scroll To Top